Improving CRISPR Genome Editing to Treat Genetic Disease

CRISPR genome editing has enormous potential as a means to treat genetic disorders, such as sickle cell disease. However, despite massive success in pre-clinical experiments, the impact of CRISPR in the clinic has been relatively limited.

One problem is a lack of options for large-scale delivery of CRISPR enzymes to patients.

Earlier this month, Aldevron and Synthego co-sponsored a GEN webinar exploring excitingnew research into how to deliver genome editing enzymes in vivo into patient cells.

Read More